Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06602193 | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | PHASE2 | ACTIVE NOT_RECRUITING | 50 | — | — | Oct 24, 2024 | Feb 28, 2028 | May 27, 2026 | 20 | United States, Germany +2 |
| Arm | Type | Description |
|---|---|---|
| BIIB122 225 mg | EXPERIMENTAL | Oral 225 mg dose, once daily (QD) |
| BIIB122 Matching Placebo | PLACEBO_COMPARATOR | Oral BIIB122 matching placebo, once daily (QD) |
| Name | Type | Description |
|---|---|---|
| BIIB122 225 mg | DRUG | Administered as specified in the treatment arm |
| BIIB122-Matching Placebo | OTHER | Administered as specified in the treatment arm |
Inclusion Criteria: * For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years * For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years * Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant. * Have a clinical diagnosis of PD meeting the Mov...